The Food and Drugs Authority (FDA) has granted market authorisation for the commercial production of Snake Anti-Venom Serum in Ghana, a move Health Minister Kwabena Mintah Akandoh says marks a turning point in the country’s pharmaceutical manufacturing journey.
Delivering a sector performance update on Friday, July 18, the Minister described the FDA’s approval as a major milestone in Ghana’s quest to become self-reliant in producing essential medical supplies.
“I am happy to inform you that one of our private sector partners has obtained market authorisation from Ghana’s FDA to produce Snake Anti-Venom Serum on a commercial scale, marking the next step in our goal to shift Ghana from a consumer to a producer,” Akandoh announced.
He explained that the approval follows active collaboration between the National Vaccine Institute, the FDA, and key pharmaceutical industry stakeholders. This, he said, reflects the regulator’s growing capacity to support innovation while ensuring safety and quality standards.
“Ladies and Gentlemen, the government has pledged and remains dedicated to making Ghana a centre for vaccine manufacturer.
“In this regard, the National Vaccine Institute is collaborating with the regulatory authority and pharmaceutical industry stakeholders to bring this plan to reality,” the Minister noted.